<DOC>
	<DOCNO>NCT01894711</DOCNO>
	<brief_summary>AIM To determine value trastuzumab early breast cancer set Netherlands . RESEARCH QUESTIONS / OBJECTIVES 1 . Is adjuvant trastuzumab daily practice effectively use , , give ? 2 . Is introduction trastuzumab early breast cancer cost-effective Netherlands ? To address research question ( objective ) , follow outcome measure determine : CLINICAL OUTCOME MEASURES 1 . Actual trastuzumab administration oppose plan trastuzumab administration 2 . Selection criterion chemotherapy trastuzumab daily practice 3 . Immediate longterm toxicity due adjuvant treatment , specifically cardiac 4 . Disease-free , breast cancer specific , overall survival relation trastuzumab ECONOMIC OUTCOME MEASURES 5 . Volumes cost diagnostic test therapy include ( distant ) relapse 6 . Cost-effectiveness trastuzumab clinical trial versus real world</brief_summary>
	<brief_title>Real World Efficiency Trastuzumab Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>All patient diagnose invasive stage IIII breast cancer year 2005 , 2006 2007 participate 5 hospital . Distant metastasis time primary diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>